Amarin Corporation plc (NASDAQ:AMRN) Q2 2022 Results Conference Call August 3, 2022 8:00 AM ET
Company Participants
Lisa DeFrancesco - SVP, IR and Corporate Affairs
Karim Mikhail - President and CEO
Dr. Steve Ketchum - President, R&D and Chief Scientific Officer
Tom Reilly - CFO
Conference Call Participants
Louise Chen - Cantor
Roanna Ruiz - SVB Securities
Daniel Wolle - JP Morgan
Operator
Welcome to Amarin Corporation’s Conference Call to discuss its Second Quarter 2022 Financial Results and Operational Update. This conference call is being recorded today, August 3, 2022. I would like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at Amarin.
Lisa DeFrancesco
Good morning, everyone, and thank you for joining us. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. We may not achieve our goals, carryout our plans or intentions or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate.
For additional information concerning the risk factors that could cause actual results to differ materially, please see the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2021 and our Form 10-Q for the quarter ended June 30, 2022, which have been filed with the SEC and are now available through the Investor Relations section of our website at www.amarincorp.com. We encourage everyone to read these documents. This call is intended for investors in Amarin and is not intended to promote the use of VASCEPA. An archive of this call will be posted on Amarin’s website in the Investor Relations section.
Karim Mikhail, Amarin’s President and Chief Executive Officer, will lead our discussion; Dr. Steve Ketchum, President of R&D and Chief Scientific Officer, will provide an update on recent clinical data and publications; and Tom Reilly, Amarin’s new Chief Financial Officer, will provide a more detailed review of our second quarter 2022 financial results. After prepared remarks, we will open the call to your questions.